FDA Postmarketing Strategy Draws On 1980 Melmon Commission Report

FDA's postmarketing safety agenda in 2002 derives in large part from the 20-year-old report of a pharmaceutical industry commission formed at the behest of Sen. Edward Kennedy (D-Mass.)